



Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting

October 31, 2023

- Two poster presentations highlighting new preclinical data with BlueRock Therapeutics –
- Two poster presentations showcasing Senti Bio's proprietary Gene Circuit platform –

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced four poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held November 1-5, 2023, in San Diego, CA.

"This continues to be a definitive year for Senti with multiple presentations across multiple medical and scientific venues," said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. "The four posters at this year's SITC meeting highlight the breadth and modularity of our platform. We also continue to make progress with our longstanding partner BlueRock, as highlighted by our two joint posters. Overall, I am pleased with the growing interest in our Gene Circuit platform throughout the global scientific community as we soon embark on using these technologies in the clinic."

The presentations and posters can be accessed on the [Scientific Presentations & Publications](#) section of the Senti Bio website.

PRESENTATIONS HIGHLIGHTS

NOT gate gene circuits expand the range of tumor-associated antigens addressable by CAR-NK and -T cell therapies

In collaboration with GeneFab LLC

Abstract number: 257

Location: Poster Halls A and B1

Date and time: November 3, 2023, 9:00 am - 7:00 pm PT

- Many tumor-associated antigens are also expressed on healthy cells, risking on-target/off-tumor toxicity.
- Senti's Bio proprietary Logic Gating can help design cell therapies that address more tumor types by increasing the therapeutic window.
- The Company's NOT Gate technology, which is used in SENTI-202, aims to protect healthy cells *in vitro* and *in vivo* without interfering with anti-cancer killing in both T cells and NK cells.

Small-molecule regulated safety switch for improved safety of CAR cell therapies in the brain

In collaboration with BlueRock Therapeutics and GeneFab LLC

Abstract number: 24

Location: Poster Halls A and B1

Date and time: November 4, 2023, 9:00 am - 8:30 pm PT

- Optimization of tamoxifen-responsive binding domains by computational design followed by high throughput screening yielded safety switches that trigger cell death via tamoxifen metabolites.
- Tamoxifen-regulated safety switch achieves complete killing at pharmacologically relevant concentrations in primary T cells within 48 hours of induction, enabling potential use in cell therapies for enhanced safety.

Smart sensor promoters drive state-specific gene circuits to convert immunosuppressive macrophages into an anti-tumor phenotype

In collaboration with BlueRock Therapeutics and GeneFab LLC

Abstract number: 430

Location: Poster Halls A and B1

Date and time: November 4, 2023, 9:00 am - 8:30 pm PT

- Putative native enhancers mined from ATAC-Seq can be engineered into strong and M2c polarization state selective promoters when paired with certain promoters.
- Generation of mutational variants of native M2 enhancers enable functional identification and mapping of regulatory elements.
- Overexpression of transcription factors can be used as a master regulator to drive an M1-like phenotype.
- State-specific promoters can be built into smart sensor circuits to control macrophage polarization logic.

High-throughput discovery of constitutive promoters to drive strong expression of next-generation gene circuits in CAR-NK and -T cells

Abstract number: 270

Location: Poster Halls A and B1

Date and time: November 4, 2023, 9:00 am - 8:30 pm PT

- Senti Bio has developed a robust platform for high-throughput promoter discovery that leverages both pooled library screening and automated end-to-end clonal screening.
- The Company's optimized promoters enable higher expression of all gene circuit components, thereby allowing Senti Bio's proprietary Logic Gated CAR cells to achieve high protection of healthy cells using the NOT Gate technology without compromising tumor-killing function.
- The data validates the Company's discovery platform to engineer constitutive promoters for complex payload expression in T cells as well as NK cells, thus enabling the ability to effectively expand the Logic Gate technology into a wide range of cancers.

About Senti Bio

Senti Biosciences is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. The Company's wholly-owned pipeline utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with Gene Circuits, to target challenging liquid and solid tumor indications. Senti Bio has also preclinically demonstrated the potential breadth Gene Circuits in other modalities, diseases outside of oncology, and continues to advance these capabilities through partnerships with Spark Therapeutics and BlueRock Therapeutics.

Forward-Looking Statements

This press release and document contain certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the words "believe," "could," "predict," "continue," "ongoing," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," "forecast," "seek," "target" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio's management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, Senti Bio's upcoming presentations; as well as statements about the potential attributes and benefits of Senti Bio's platform technology. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Senti Bio. Many factors could cause actual future results to differ materially from the forward-looking statements in this document, including but not limited to: (i) changes in domestic and foreign business, market, financial, political and legal conditions, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, changes in laws and regulations affecting Senti Bio's business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and a changing regulatory landscape in Senti Bio's highly competitive industry, (v) risks relating to the uncertainty of any projected financial information with respect to Senti Bio, (vi) risks related to uncertainty in the timing or results of Senti Bio's preclinical studies, IND filings, and GMP manufacturing startup activities, (vii) Senti Bio's dependence on third parties in connection with preclinical and IND-enabling studies, IND filings, and GMP manufacturing activities, (viii) risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates on business operations, and (ix) the success of any future research and development efforts by Senti Bio. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Senti Bio's most recently filed periodic report, and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not presently know, or that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio's assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

Availability of Other Information About Senti Biosciences, Inc.

For more information, please visit the Senti Bio website at <https://www.sentibio.com> or follow Senti Bio on Twitter (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Senti Bio Contact

Investors: investors@sentibio.com

Media: media@sentibio.com